Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Hundreds of Fosamax lawsuits versus Merck ordered readied for trial

share with twitter share with LinkedIn share with facebook
share via e-mail
08/30/2013 | 10:53pm CEST

A federal judge overseeing consolidated litigation against Merck & Co over jaw injuries allegedly caused by the osteoporosis drug Fosamax has ordered hundreds of cases be dispersed to courts across the country for trial.

The decision by U.S. District Judge John Keenan in Manhattan marks an unusual and potentially costly development for Merck.

Companies often find it easier to reach settlements in mass tort cases that are consolidated before one judge.

"It's a big deal as it changes the cost paradigm for Merck exponentially," said Timothy O'Brien, a partner at Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor and lawyer representing Fosamax plaintiffs.

The judge's order Thursday requires that 200 cases per month be sent to back to courts where they were initially filed, beginning with the oldest ones.

Lainie Keller, a spokeswoman for Merck, said the company "is committed to defending its conduct in regard to Fosamax and has confidence in its defense strategy that has had so much success in the courts."

The cases before Keenan comprised roughly one-fifth of the 5,075 lawsuits pending nationally in federal and state courts related to Fosamax, a one-time blockbuster medication.

Lawsuits alleging that plaintiffs developed osteonecrosis of the jaw from Fosamax were consolidated before Keenan in 2006.

The judge conducted a series of "bellwether" trials, allowing the parties to assess trends and outcomes in similar cases. A series of wins for plaintiffs, for example, can put them in a better position for settlement talks.

The final Fosamax bellwether trial before Keenan ended in February with a $285,000 verdict for plaintiff Rhoda Scheinberg.

Merck lost just one other of the five bellwether trials before Keenan, when a jury in 2010 awarded Florida resident Shirley Boles $8 million, a sum the judge reduced to $1.5 million.

Keenan's order on Friday came after mediation to resolve 370 cases broke down two weeks ago. O'Brien's law firm and another firm represented plaintiffs in those cases.

Another 104 lawsuits brought by another firm could have been added to the talks if a deal on value was reached, O'Brien said.

Lawyers for the plaintiffs had sought to have 300 cases transferred every four months, while Merck sought to have just 100 cases scheduled for discovery over a six-month period.

Merck has benefited from having the litigation consolidated.

Keenan had thrown out 430 cases after he issued an order last November, which Merck had sought, requiring them to put forth expert reports showing scientific proof of their claims.

But in his order Friday, Keenan said Merck's latest proposal would "unnecessarily prolong" the proceedings before him.

Keenan ordered plaintiffs to recommend by October 11 where to sent the first batch of cases.

An order moving so many personal injury cases home at once is rare, O'Brien said. He noted that Merck reached a $4.85 billion settlement with over the painkiller Vioxx in 2007 only after a federal judge threatened a similar order.

"I anticipate Merck will continue talking and seek to resolve the cases," O'Brien said. "The opportunity is there."

The case is In Re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York, No. 06-md-01789.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

By Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
01:06p MERCK AND : Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune..
09/21 MERCK AND : MSD`s Keytruda wins new bladder cancer indication in Europe
09/19 MERCK AND : Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Me..
09/14 MERCK AND : Rigontec Acquired by MSD
09/14 MERCK AND COMPANY : ex-dividend day
09/12 NOW AVAILABLE IN CANADA : ISENTRESS® HD (raltegravir), a New Once-Daily Option, ..
09/12 MERCK AND : KEYTRUDA Plus Pemetrexed and Carboplatin Demonstrated Continued Bene..
09/12 MERCK AND : KEYTRUDA Continues to Show Overall Survival Benefit over Chemotherap..
09/12 MERCK AND : Updated Data for Merck's KEYTRUDA in Patients with Advanced Gastric ..
09/12 MERCK AND : Incyte chalk up promising melanoma data for Keytruda-epacadostat com..
More news
News from SeekingAlpha
09:34a REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
09/21 FDA's Woodcock says clinical trials system "broken"
09/21 Mirati Brings Hope With Its Stellar Performance
09/21 Hold On To Zoetis In 2017
09/18 NOVARTIS : The Value Creator
Financials ($)
Sales 2017 40 323 M
EBIT 2017 13 721 M
Net income 2017 5 623 M
Debt 2017 5 469 M
Yield 2017 2,87%
P/E ratio 2017 32,75
P/E ratio 2018 19,58
EV / Sales 2017 4,57x
EV / Sales 2018 4,46x
Capitalization 179 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,1 $
Spread / Average Target 6,9%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.75%178 914
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
SANOFI9.06%126 655